IL17A and neoplasm: Li et al. demonstrated that the neutral sphingomyelinase inhibitor GW4869 significantly inhibits tumor growth in xenograft models by reducing the proliferation, migration, and invasion of SCC7-EV cells (mouse OSCC) and decreasing the expression of IL-17A pathway molecules [117].